Our results showed that IL-6 (receptor) antagonists were associated with a reduction in mortality, a reduction in mechanical ventilation and a reduction in the composite endpoint of mortality and mechanical ventilation for COVID-19 patients based on moderate to high certainty evidence. The gene discussed is IL6; the disease is COVID-19.